PharmaLex Group has completed a merger with BioStat Solutions (BSSI).
BSSI provides analytical expertise in clinical, bioinformatics and translational medicine research including the design, analysis, and interpretation of complex data to pharmaceutical and biotechnology companies.
Following the merger with PharmaLex, Dr Lin Li will take over management of BSSI. Ron Bromley will step down as CEO, while BSSI’s other founder, Dr Ena Bromley, will continue to provide support as non-executive director and principal consultant.
“PharmaLex is a leading service provider in the pharma, biotech and medical device industries”, explained Lin Li, Senior Director of Scientific Operations, BioStat Solutions. “It is an exciting challenge to support them in developing their statistical solutions services and I look forward to leading the US team”, he added.
“BSSI has provided a standard of excellence in the industry”, said Dr. Bruno Boulanger, Chief Scientific Officer, PharmaLex. “We are very excited about this collaboration and the new possibilities it presents for our existing statistical services”.
“BSSI has had a focus on translational medicine and bioinformatics”, said Dr. Thomas Dobmeyer, CEO PharmaLex. “Their service portfolio complements nicely with our existing statistical solutions which focuses more on Bayesian statistics and will allow us to further enhance the services we are able to offer our clients – within the growing biomarker and bioinformatics market, which are both expected to grow with >13% per annum”, he added.